Lupin on Thursday said it has received correspondence from the USFDA that it has now addressed the concerns raised in the Warning Letter for its facilities in Goa and Pithampur Unit-2, Indore. Nilesh Gupta, MD of Lupin, said, “We are pleased to be informed by the USFDA that we have addressed the concerns through our corrective actions related to the November 2017 Warning Letter.”
